April 10, 2022 12:00 PM EDTUpdated April 11, 06:32 AM

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

Max Gelman

Senior Editor

NEW ORLEANS — Amgen attempted to further pull away from Mirati Therapeutics in the KRAS space, touting a new batch of long-term non-small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati